Discussion
The U.S. Food and Drug Administration (FDA) has approved a new oral solution formulation of Evoxac (cevimeline hydrochloride), a long-used treatment for dry mouth in adults with Sjögren’s disease, offering an alternative for patients who have difficulty swallowing capsules. Developed by Cosette Pharmaceuticals, the new formulation contains…